Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Vnitrni Lekarstvi 1991-Jan

[Changes in plasma lipids, lipoproteins and utilization of energy substrates during continuous enteral nutrition with 50% medium chain triacylglycerols (Preciten MCT 50)].

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Link salvestatakse lõikelauale
Z Zadák
L Sobotka
J Horácek
B Cervenka

Märksõnad

Abstraktne

Enteral nutrition (EN) containing part of the energy substrates in the form of triacylglycerols with medium chain fatty acids (MCT) has a number of advantages in particular in patients with an impaired utilization of energy and impaired nutrient absorption from the small intestine. The increased MCT supply reduces the risk of the development of shock lung, consumption coagulopathy and has a very favourable effect in patients with severe catabolism associated with Crohn's disease. On the other hand EN containing MCT may produce also some undesirable effects such as deterioration of glucose utilization in the liver, changes, on the composition of plasma lipids and lipoproteins and an undesirable thermogenic effect. Investigations of the effect of EN containing 50% of fat in the form of MCT (Preciten MCT 50R, Sandoz Nutrition-Wander) indicate that even an energy supply corresponding to 1.7 X REE in the form of EN with 50% MCT does not lead to a statistically significant rise of REE, does not produce a marked thermogenic effect and the value of the respiratory quotient (RQ) does not increase significantly. Already after 8 days of EN significant changes occur in the spectrum of lipids and lipoproteins characterized by a decline of high density lipoproteins HDL3 (p less than 0.05). The parallel decline of low density lipoproteins LDL and VLDL, however, is the reason why adverse changes of the atherogenic index do not occur.

Liitu meie
facebooki lehega

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus

  • Töötab 55 keeles
  • Taimsed ravimid, mida toetab teadus
  • Maitsetaimede äratundmine pildi järgi
  • Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
  • Lugege oma otsinguga seotud teaduspublikatsioone
  • Otsige ravimtaimi nende mõju järgi
  • Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega

Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel

Google Play badgeApp Store badge